Reply to Auclin et al. Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021 13 1176

摘要

We thank Auclin et al. [1] for the comments on our manuscript in Cancers titled “Value of the Lung Immune Prognostic Index (LIPI) in Patients with Non-Small Cell Lung Cancer (NSCLC) Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMpower150 Trial” [2]. We read with interest the elements of the approach proposed by Auclin et al.’s [1] to integrate LIPI into routine clinical practice and, specifically: (1) to validate LIPI retrospectively in previous clinical trials with immunotherapy; (2) to design prospective clinical trials including LIPI as a stratification factor; and (3) to design prospective clinical trials using LIPI as a marker for guiding treatment selection. However, caution is required to ensure the development of ‘host-related inflammatory indices’ for immunotherapies are well planned and target the key factors enabling precision immunotherapy use in oncology.